Reed International PLC
26 February 2002
LETTER TO COMPANY ANNOUNCEMENTS OFFICE
ISSUED ON BEHALF OF REED INTERNATIONAL P.L.C. AND ELSEVIER NV
Director Shareholding
We are writing to advise you that we received notifications yesterday that the
following grants of options were made to directors of Reed International P.L.C.
and Elsevier NV on 22 February 2002, under the Reed Elsevier plc Executive Share
Option Scheme:
Date of Director No. of Reed No. of Elsevier Exercisable
Grant International shares over
shares over which an option
which an option has been granted
has been granted at €13.94 per share
at 600p per share
22.02.2002 C H L Davis 148,500 104,204 2005-2012
22.02.2002 M H Armour 74,000 51,926 2005-2012
22.02.2002 G J A van de Aast 58,000 40,699 2005-2012
22.02.2002 D J Haank 59,843 41,993 2005-2012
22.02.2002 A Prozes 103,722 72,783 2005-2012
Exercise of the above options is subject to the earnings per share performance
conditions, as described in the company's Annual Financial Statements.
LETTER FROM REED ELSEVIER PLC
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.